{"generic":"Peginterferon Alfa-2a","drugs":["Pegasys","Pegasys Proclick","Peginterferon Alfa-2a"],"mono":[{"id":"jvajs0","title":"Generic Names","mono":"Peginterferon Alfa-2a"},{"id":"jvajs1","title":"Dosing and Indications","sub":[{"id":"jvajs1b4","title":"Adult Dosing","mono":"<ul><li>Evaluate renal function and CBC results before treatment.<\/li><li>Monotherapy not recommended unless significant contraindication or intolerance to ribavirin is present.<\/li><li><b>Active type B viral hepatitis, chronic:<\/b> monotherapy, 180 mcg SUBQ once a week for 48 weeks<\/li><li><b>Essential thrombocythemia:<\/b> Initial, 90 mcg\/wk SUBQ; dose modification based on efficacy and toxicity (study dose)<\/li><li><b>Hepatitis C, chronic, In combination with other hepatitis C virus antiviral drugs in patients with compensated liver disease:<\/b> (Genotype 1 or 4) 180 mcg SUBQ once a week; duration of therapy is 48 weeks in combination with ribavirin only; discontinue therapy for genotype 1 if at least a 2 log(10) reduction from baseline in hepatitis C virus (HCV) RNA titer is not seen by 12 weeks of treatment or if undetectable HCV RNA is not achieved after 24 weeks of treatment<\/li><li><b>Hepatitis C, chronic, In combination with other hepatitis C virus antiviral drugs in patients with compensated liver disease:<\/b> (Genotype 2 or 3) 180 mcg SUBQ once a week; duration of therapy is 24 weeks in combination with ribavirin only<\/li><li><b>Hepatitis C, chronic, In combination with other hepatitis C virus antiviral drugs in patients with compensated liver disease:<\/b> (HIV coinfection) 180 mcg subQ once a week for 48 weeks regardless of HCV genotype<\/li><li><b>Hepatitis C, chronic, Monotherapy for patients with compensated liver disease and contraindications to or intolerance of other hepatitis C antiviral drugs:<\/b> 180 mcg subQ once a week for 48 weeks; discontinue therapy for genotype 1 if at least a 2 log(10) reduction from baseline in hepatitis C virus (HCV) RNA titer is not seen by 12 weeks of treatment or if undetectable HCV RNA is not achieved after 24 weeks of treatment<\/li><li><b>Polycythemia vera:<\/b> Initial, 90 mcg\/week SUBQ; dose modification based on efficacy and toxicity  or escalated every 2 weeks as tolerated to 135 mcg\/wk; may escalate to 180 mcg\/wk in the absence of hematologic response; treatment continued as long as clinically beneficial<\/li><\/ul>"},{"id":"jvajs1b5","title":"Pediatric Dosing","mono":"<ul><li>Evaluate renal function and CBC results before treatment.<\/li><li>Monotherapy not recommended unless significant contraindication or intolerance to ribavirin is present.<\/li><li><b>Hepatitis C, chronic, In combination with other hepatitis C virus antiviral drugs in patients with compensated liver disease:<\/b> (5 years or older) 180 mcg\/1.73 m(2) x body surface area (to maximum of 180 mcg) subQ once a week in combination with ribavirin; duration of therapy is 24 weeks for genotype 2 or 3 and 48 weeks for other genotypes<\/li><\/ul>"},{"id":"jvajs1b6","title":"Dose Adjustments","mono":"<ul><li><b>Hepatic impairment, adult, chronic hepatitis C:<\/b> Reduce to 135 mcg\/wk and monitor liver function; withhold therapy if needed; may be resumed after ALT flares subside; immediately discontinue therapy if ALT increases are progressive despite dose reduction or accompanied by increases in bilirubin or evidence of hepatic decompensation<\/li><li><b>Hepatic impairment, pediatric, hepatitis C:<\/b> Reduce to 135 mcg\/1.73 m(2) x body surface area (BSA) once weekly for increasing or persistent ALT elevations 5 to less than 10 times the ULN; monitor ALT weekly; reduce dose if indicated until ALT decreases or stabilizes; discontinue therapy if ALT remains 10 times the ULN or greater despite dose reduction<\/li><li><b>Hepatic impairment, adult, chronic hepatitis B:<\/b> In patients with an elevation of ALT greater than 5 times ULN, consider reducing dose to 135 mcg\/wk or temporarily discontinuing; monitor liver function; therapy may be resumed after ALT flares subside; if severe persistent hepatitis B flares (ALT greater than 10 times above the ULN), consider discontinuation of therapy; immediately discontinue if ALT increases are progressive despite dose reduction or are accompanied by increases in bilirubin or evidence of hepatic decompensation<\/li><li><b>Renal impairment, adult, CrCl 30 to 50 mL\/min:<\/b> Adjustment not required<\/li><li><b>Renal impairment, adult, CrCl less than 30 mL\/min or ESRD requiring hemodialysis:<\/b> Reduce to 135 mcg\/wk; if severe adverse reactions develop, reduce to 90 mcg\/wk; if intolerance persists, discontinue therapy<\/li><li><b>Renal impairment, pediatric:<\/b> Has not been evaluated<\/li><li><b>Depression, adult:<\/b> Mild depression, no change required; evaluate weekly by phone or visit; moderate depression, reduce to 135 mcg\/wk; may require reduction to 90 mcg\/wk; evaluate weekly, with office visit at least every other week; if symptoms remain stable, continue reduced dose; if symptoms improve and are stable for 4 weeks, resume normal visit schedule and continue reduced dose or increase to normal dose; severe depression, discontinue peginterferon alfa-2a therapy permanently and obtain immediate psychiatric consultation<\/li><li><b>Depression, pediatric:<\/b> Mild depression, no change required; evaluate weekly by phone or visit; moderate depression, reduce dose to 135 mcg\/1.73 m(2) x body surface area (BSA) once weekly; may require reduction to 90 mcg\/1.73 m(2) x BSA once weekly; evaluate weekly, with office visit at least every other week; if symptoms remain stable, continue reduced dose; if symptoms improve and are stable for longer than 4 weeks, resume normal visit schedule and continue reduced dose or return to normal dose; severe depression, discontinue peginterferon alfa-2a therapy permanently and obtain immediate psychiatric consultation<\/li><li><b>Neutropenia, adult:<\/b> For absolute neutrophil count (ANC) less than 750 cells\/mm(3), decrease dose to 135 mcg\/wk; for ANC less than 500 cells\/mm(3), delay until ANC is greater than 1000 cells\/mm(3), then restart with dose reduced to 90 mcg\/wk and monitor ANC<\/li><li><b>Neutropenia, pediatric, ANC 750 to 999 cells\/mm(3):<\/b> During weeks 1 or 2 of therapy, reduce dose to 135 mcg\/1.73 m(2) x BSA once weekly; during weeks 3 to 48 of therapy, no adjustment needed<\/li><li><b>Neutropenia, pediatric, ANC 500 to 749 cells\/mm(3):<\/b> During weeks 1 or 2 of therapy, delay dose until ANC greater than 750 cells\/mm(3), then resume at 135 mcg\/1.73 m(2) x BSA once weekly; monitor ANC weekly for 3 consecutive readings above 750 cells\/m(3); during weeks 3 to 48 of therapy, reduce to 135 mcg\/1.73 m(2) x BSA once weekly<\/li><li><b>Neutropenia, pediatric, ANC 250 to 499 cells\/mm(3):<\/b> During weeks 1 or 2 of therapy, delay dose until ANC greater than 750 cells\/mm(3), then resume at 90 mcg\/1.73 m(2) x BSA once weekly; during weeks 3 to 48 of therapy, delay dose until ANC greater than 750 cells\/mm(3), then resume at 135 mcg\/1.73 m(2) x BSA once weekly<\/li><li><b>Neutropenia, pediatric, ANC less than 250 cells\/mm(3) or with febrile neutropenia:<\/b> Discontinue therapy<\/li><li><b>Thrombocytopenia, adult:<\/b> For platelet count less than 50,000 cells\/mm(3), decrease dose to 90 mcg\/wk; for platelet count less than 25,000 cells\/mm(3), discontinue treatment<\/li><li><b>Thrombocytopenia, pediatric, platelet count less than 50,000 cells\/mm(3):<\/b> Decrease dose to 90 mcg\/1.73 m(2) x BSA once weekly<\/li><\/ul>"},{"id":"jvajs1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Active type B viral hepatitis, chronic<\/li><li>Hepatitis C, chronic, In combination with other hepatitis C virus antiviral drugs in patients with compensated liver disease<\/li><li>Hepatitis C, chronic, Monotherapy for patients with compensated liver disease and contraindications to or intolerance of other hepatitis C antiviral drugs<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Essential thrombocythemia<\/li><li>Hepatitis C, chronic, Interferon alfa\/ribavirin nonresponders<\/li><li>Polycythemia vera<\/li><\/ul>"}]},{"id":"jvajs2","title":"Black Box Warning","mono":"<b>Subcutaneous (Solution)<\/b><br\/>Alpha interferons may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Clinical and laboratory monitoring is recommended. If severe or worsening signs or symptoms of these conditions occur, treatment should be discontinued.<br\/>"},{"id":"jvajs3","title":"Contraindications\/Warnings","sub":[{"id":"jvajs3b9","title":"Contraindications","mono":"<ul><li>hepatic decompensation (Child-Pugh score greater than 6 (class B and C)) in cirrhotic patients before treatment<\/li><li>hepatic decompensation (Child-Pugh score greater than or equal to 6) in cirrhotic patients co-infected with hepatitis C and HIV before treatment<\/li><li>autoimmune hepatitis<\/li><li>hypersensitivity reactions, including urticaria, angioedema, bronchoconstriction, anaphylaxis, or Stevens-Johnson syndrome to alfa interferons or any component of the product<\/li><li>men taking concomitant ribavirin with a pregnant female partner<\/li><li>neonates and infants; peginterferon alfa-2a contains benzyl alcohol<\/li><li>pregnancy with concomitant ribavirin use; may cause birth defects and death of the exposed fetus<\/li><\/ul>"},{"id":"jvajs3b10","title":"Precautions","mono":"<ul><li>Black Box Warning:<\/li><li>-- Alpha interferons may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders; clinical and laboratory monitoring required, discontinue use if suspected<\/li><li>Cardiovascular:<\/li><li>-- Hypertension, supraventricular arrhythmias, chest pain, and myocardial infarction have been reported<\/li><li>-- Pre-existing cardiac disease; use caution<\/li><li>-- History of significant or unstable cardiac disease; avoid use with ribavirin<\/li><li>Dermatologic:<\/li><li>-- Serious skin reactions, such as vesiculobullous eruptions, erythema multiforme major, and other reactions in the spectrum of Stevens-Johnson Syndrome have been reported with varying degrees of skin and mucosal involvement and exfoliative dermatitis (erythroderma); discontinue use if suspected<\/li><li>Endocrine:<\/li><li>-- New onset or exacerbation of existing hypothyroidism or hyperthyroidism may occur; discontinue use if uncontrolled with medication<\/li><li>-- Hyperglycemia, hypoglycemia, and diabetes mellitus have been reported; discontinue use if uncontrolled with medication<\/li><li>-- Uncontrolled hyperglycemia, hypoglycemia, and diabetes mellitus; avoid use<\/li><li>Gastrointestinal:<\/li><li>-- Ulcerative and hemorrhagic\/ischemic colitis, sometimes fatal, has been reported within 12 weeks of initiating treatment; discontinue use if suspected<\/li><li>-- Pancreatitis, sometimes fatal, has been reported with concomitant ribavirin use; suspend use if suspected and discontinue use if diagnosis confirmed<\/li><li>Hematologic:<\/li><li>-- Bone marrow suppression resulting in severe cytopenias may occur; aplastic anemia may occur under rare circumstances; CBC monitoring prior to and during treatment is recommended<\/li><li>-- Severe neutropenia and thrombocytopenia which may result in serious infection or bleeding may occur at a higher incidence in HIV coinfected patients<\/li><li>-- Neutropenia and lymphopenia may be potentiated by concomitant ribavirin use<\/li><li>-- In patients with baseline neutrophil counts less than 1500 cells\/mm(3), baseline platelet counts less than 90,000 cells\/mm(3), or baseline hemoglobin less than 10 g\/dL use with concomitant ribavirin should be done with caution; discontinue use if severe decreases in neutrophil and\/or platelet counts occur<\/li><li>-- Pancytopenia and bone marrow suppression have been reported with concomitant ribavirin and azathioprine use; discontinue use if pancytopenia is suspected<\/li><li>Hepatic:<\/li><li>-- Hepatic decompensation and death may occur in cirrhotic patients, this risk may be increased in those coinfected with HIV and receiving highly active antiretroviral therapy; monitoring recommended and discontinue use if suspected<\/li><li>-- Exacerbation of hepatitis with transient and potentially severe increases in serum ALT may occur; monitoring and dosage adjustment recommended; discontinue use if ALT increases despite dose adjustments or if accompanied by increasing bilirubin or evidence of hepatic decompensation<\/li><li>Immunologic:<\/li><li>-- Autoimmune disorders (eg, myositis, hepatitis, thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura, psoriasis, rheumatoid arthritis, interstitial nephritis, thyroiditis, and systemic lupus erythematosus) have been reported; use with caution in patients with pre-existing autoimmune disorders<\/li><li>-- Severe and fatal infections (bacterial, viral, or fungal) have been reported; consider discontinuing interferon therapy particular in neutropenic patients with fever and flu-like symptoms<\/li><li>-- Severe acute hypersensitivity reactions (eg, urticaria, angioedema, bronchoconstriction, and anaphylaxis) have been reported with concomitant ribavirin use; discontinue use if suspected<\/li><li>Neurologic:<\/li><li>-- Ischemic and hemorrhagic cerebrovascular events have been reported, some cases occurred in patients with no risk factors<\/li><li>-- Peripheral neuropathy has been reported with concomitant telbivudine use<\/li><li>Ophthalmic:<\/li><li>-- Ophthalmologic disorders (eg, decrease or loss of vision, retinopathy, including macular edema, optic neuritis, papilledema and serous retinal detachment) may be induced or aggravated; baseline eye examinations recommended, continued monitoring recommended in patients with pre-existing ophthalmologic disorders (eg, diabetic or hypertensive retinopathy); discontinuation may be required<\/li><li>Psychiatric:<\/li><li>-- Aggressive behavior, psychoses, hallucinations, bipolar disorders, and mania have been reported; monitoring recommended; discontinue use if severe symptoms are observed<\/li><li>-- History of depression; use with caution<\/li><li>Renal:<\/li><li>--renal impairment, severe (CrCl less than 30 mL\/min or hemodialysis); increased risk of interferon toxicity; monitoring and dose adjustments are recommended; discontinue if severe lab abnormalities or adverse effects occur<\/li><li>Respiratory:<\/li><li>-- New onset or exacerbation of pulmonary disorders (eg, dyspnea, pulmonary infiltrates, pulmonary hypertension, pneumonia, bronchiolitis obliterans, interstitial pneumonitis, sarcoidosis) may occur, some cases have resulted in respiratory failure and death; suspend treatment if pulmonary infiltrates or pulmonary function impairment occurs and monitor closely if restarted<\/li><li>Other:<\/li><li>-- Growth delay may occur in pediatric patients with concomitant ribavirin use<\/li><\/ul>"},{"id":"jvajs3b11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>B3 (AUS)<\/li><\/ul>"},{"id":"jvajs3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},{"id":"jvajs4","title":"Drug Interactions","sub":[{"id":"jvajs4b13","title":"Contraindicated","mono":"<ul>Telbivudine (probable)<\/ul>"},{"id":"jvajs4b14","title":"Major","mono":"<ul>Theophylline (probable)<\/ul>"},{"id":"jvajs4b15","title":"Moderate","mono":"<ul>Methadone (established)<\/ul>"}]},{"id":"jvajs5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Alopecia (18% to 28%), Dermatitis (8% to 16%), Dry skin (4% to 10%), Injection site inflammation (10% to 31%), Injection site reaction (pediatric, 44%), Injection site reaction (22% to 23%), Pruritus (12% to 19%), Rash (adult, 5% to 8%; pediatric, 15%)<\/li><li><b>Endocrine metabolic:<\/b>Serum triglycerides raised (2% to 36%), Weight decreased (Adult, 16%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (8% to 26%), Diarrhea (11% to 31%), Loss of appetite (16% to 24%), Nausea and vomiting (5% to 25%)<\/li><li><b>Musculoskeletal:<\/b>Arthralgia (22% to 28%), Myalgia (26% to 51%)<\/li><li><b>Neurologic:<\/b>Dizziness (13% to 23%), Headache (27% to 60%), Insomnia (19% to 30%), Reduced concentration (8% to 10%)<\/li><li><b>Psychiatric:<\/b>Anxiety, Feeling nervous, Irritability<\/li><li><b>Respiratory:<\/b>Cough (4% to 10%), Dyspnea (4% to 13%)<\/li><li><b>Other:<\/b>Fatigue (adult, 24% to 67%; pediatric, 25%), Fever (24% to 54%), Influenza-like illness (pediatric, 91%), Rigor (25% to 47%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Myocardial infarction, Supraventricular arrhythmia<\/li><li><b>Dermatologic:<\/b>Erythroderma, Stevens-Johnson syndrome<\/li><li><b>Gastrointestinal:<\/b>Colitis (less than 1%), Gastrointestinal hemorrhage (less than 1%), Pancreatitis (less than 1%)<\/li><li><b>Hematologic:<\/b>Anemia (2% to 14%), Aplastic anemia (less than 1%), Cytopenia, Lymphocytopenia (3% to 14%), Neutropenia (21% to 40%), Thrombocytopenia (5% to 8%), Thrombotic thrombocytopenic purpura (less than 1%)<\/li><li><b>Hepatic:<\/b>Graft rejection, Liver, Liver failure<\/li><li><b>Immunologic:<\/b>Autoimmune disease (less than 1%), Graft rejection, Liver, Graft rejection, Renal, Hypersensitivity reaction<\/li><li><b>Musculoskeletal:<\/b>Myositis (less than 1%)<\/li><li><b>Neurologic:<\/b>Cerebral hemorrhage (less than 1%), Cerebral ischemia, Coma (less than 1%), Peripheral neuropathy (less than 1%), Seizure<\/li><li><b>Ophthalmic:<\/b>Corneal ulcer (less than 1%), Retinal hemorrhage, Serous retinal detachment, Thrombosis of retinal artery, Thrombosis of retinal vein<\/li><li><b>Psychiatric:<\/b>Depression (18% to 20%), Psychotic disorder (Less than 1%), Suicide<\/li><li><b>Renal:<\/b>Graft rejection, Renal<\/li><li><b>Respiratory:<\/b>Pulmonary embolism (less than 1%)<\/li><li><b>Other:<\/b>Bacterial infectious disease (5% or less), Infectious disease<\/li><\/ul>"},{"id":"jvajs6","title":"Drug Name Info","sub":{"0":{"id":"jvajs6b17","title":"US Trade Names","mono":"<ul><li>Pegasys<\/li><li>Pegasys Proclick<\/li><\/ul>"},"2":{"id":"jvajs6b19","title":"Class","mono":"<ul><li>Antineoplastic Agent<\/li><li>Immune Suppressant<\/li><li>Immunological Agent<\/li><li>Interferon, Alfa (class)<\/li><\/ul>"},"3":{"id":"jvajs6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jvajs6b21","title":"Generic Availability","mono":"No<br\/>"}}},{"id":"jvajs7","title":"Mechanism Of Action","mono":"Peginterferon alfa-2a is a covalent conjugate of recombinant alfa-2a interferon, which is the biologically active component. Peginterferon alfa-2a binds to the human type 1 interferon receptor and induces the innate antiviral immune response.<br\/>"},{"id":"jvajs8","title":"Pharmacokinetics","sub":[{"id":"jvajs8b23","title":"Absorption","mono":"<ul><li>Tmax, SubQ: 72 to 96 hours<\/li><li>Tmax, SubQ, chronic hepatitis C: 45 to 80 hours<\/li><li>Bioavailability, SubQ: 60% or greater<\/li><\/ul>"},{"id":"jvajs8b24","title":"Distribution","mono":"Vd: 8 to 12 L.<br\/>"},{"id":"jvajs8b25","title":"Metabolism","mono":"Liver: extent unknown <br\/>"},{"id":"jvajs8b26","title":"Excretion","mono":"<ul><li>Renal clearance: hepatitis C patients, 0.06 L\/hr<\/li><li>Total body clearance: 94 mL\/hr<\/li><li>Total body clearance, severe renal impairment: 43% lower<\/li><\/ul>"},{"id":"jvajs8b27","title":"Elimination Half Life","mono":"160 hours <br\/>"}]},{"id":"jvajs9","title":"Administration","mono":"<b>Subcutaneous<\/b><br\/><ul><li>Use vial, prefilled syringe, and autoinjector at room temperature; allow for condensation on outside of the prefilled syringe or autoinjector to disappear before use.<\/li><li>Do not shake vial, prefilled syringe, or autoinjector.<\/li><li>Administer subQ in thigh or abdomen.<\/li><li>Administer on same day of each week at about the same time.<\/li><\/ul>"},{"id":"jvajs10","title":"Monitoring","mono":"<ul><li>hepatitis B virus-DNA titer, virologic response indicates efficacy<\/li><li>hepatitis B: hepatic function closely during therapy; if ALT is greater than 5 times the ULN, especially if accompanied by increases in bilirubin or evidence of hepatic decompensation, more frequent monitoring is recommended<\/li><li>HCV-RNA titers; reduction from baseline of at least 2 log(10) by week 12 of therapy or undetectable HCV-RNA after 24 weeks of therapy is evidence of efficacy; if failure to achieve this reduction it is unlikely to achieve a sustained viral response<\/li><li>hepatitis C: hepatic function closely during therapy; if there are progressive increases in ALT above baseline, especially if accompanied by increases in bilirubin or evidence of hepatic decompensation, more frequent monitoring should be performed<\/li><li>autoimmune disorders, development or worsening; periodically during therapy; including myositis, hepatitis, thrombotic and idiopathic thrombocytopenic purpura, psoriasis, rheumatoid arthritis, interstitial nephritis, thyroiditis, and systemic lupus erythematosus<\/li><li>infectious disorders, development or worsening; periodically during therapy, especially if high or persistent fever and in patients with neutropenia<\/li><li>ischemic disorders, development or worsening; periodically during therapy<\/li><li>neuropsychiatric adverse events, development or worsening; periodically during therapy; especially in patients with history of depression; including depression, suicidality, other unusual changes in behavior, aggressive behavior, psychoses, hallucinations, suicidal ideation, homicidal ideation, relapse of drug addiction, bipolar disorders, and mania<\/li><li>CBC (including hemoglobin, WBC, and platelet count); at 2 weeks and at 4 weeks of treatment, and periodically thereafter; more frequently throughout treatment if abnormalities develop<\/li><li>blood glucose; at 4 weeks and periodically during treatment<\/li><li>pregnancy test; in patients receiving concomitant ribavirin; monthly during therapy and for 6 months after discontinuation of treatment<\/li><li>renal function; in all patients receiving concomitant ribavirin and serum creatinine and signs of peginterferon alfa-2a toxicity during therapy in patients with impaired renal function<\/li><li>signs and symptoms of pancreatitis; at 4 weeks and periodically during treatment<\/li><li>thyroid function (TSH and T4); at 4 weeks and periodically during treatment<\/li><li>ECG; in patients receiving concomitant ribavirin with preexisting cardiac abnormalities; prior to initiation of therapy and as appropriate during therapy<\/li><li>ophthalmologic examination; baseline, for all patients and during therapy for patients with preexisting ophthalmologic disorders; promptly perform a complete eye exam in any patient exhibiting ocular symptoms<\/li><li>signs and symptoms of colitis<\/li><li>signs and symptoms of hepatic decompensation, hepatic failure, and exacerbations of hepatitis<\/li><li>signs and symptoms of hypersensitivity reactions including anaphylaxis and serious skin reactions<\/li><li>signs and symptoms of pulmonary disorders including respiratory failure in patients with a history of pulmonary infiltrates or impaired pulmonary function during previous administration of peginterferon alfa-2a<\/li><\/ul>"},{"id":"jvajs11","title":"How Supplied","mono":"<ul><li><b>Pegasys<\/b><br\/><ul><li>  Kit: 180 MCG\/ML<\/li><li>Subcutaneous Solution: 180 MCG\/0.5 ML<\/li><\/ul><\/li><li><b>Pegasys Proclick<\/b><br\/>Subcutaneous Solution: 135 MCG\/0.5 ML, 180 MCG\/0.5 ML<br\/><\/li><\/ul>"},{"id":"jvajs12","title":"Toxicology","sub":[{"id":"jvajs12b31","title":"Clinical Effects","mono":"<b>INTERFERONS<\/b><br\/>OVERDOSE: Data are limited. Shivers, myalgias, low grade fever and tachycardia have been reported. ADVERSE EFFECTS: \"flu-like\" symptoms (fever, chills, tachycardia, headache, malaise, and myalgias), hypotension, seizures, headache, lethargy, fatigue, elevated liver enzymes, leukopenia, & renal insufficiency; dysrhythmias in patients with underlying heart disease. Vomiting, diarrhea, hyperkalemia, hypocalcemia occur at high doses.<br\/>"},{"id":"jvajs12b32","title":"Treatment","mono":"<b>INTERFERONS<\/b><br\/><ul><li>Decontamination: Not indicated; broken down in the gut on oral ingestion.<\/li><li>Influenza-like illness: Treat with acetaminophen or non-steroidal anti-inflammatory agents<\/li><li>Hypotensive episode: Transient, usually requires no treatment;  0.9% NaCl 10-20 ml\/kg, dopamine, epinephrine if persistent<\/li><li>Monitoring of patient: CBC, hepatic &amp; renal function; ECG, calcium, potassium if severe overdose.<\/li><\/ul>"},{"id":"jvajs12b33","title":"Range of Toxicity","mono":"<b>INTERFERONS<\/b><br\/>Single doses greater than 100-200 million units associated with toxicity. <br\/>"}]},{"id":"jvajs13","title":"Clinical Teaching","mono":"<ul><li>Adverse effects to a fetus may be caused by either male or female patients receiving this drug in combination with ribavirin. Emphasize the use of reliable contraception. This applies during treatment and up to 6 months after therapy ends.<\/li><li>Patient should avoid activities requiring mental alertness or coordination until drug effects are realized, as drug may cause dizziness.<\/li><li>Drug may cause fatigue\/asthenia, pyrexia, insomnia, myalgia, and headache.<\/li><li>Instruct patient to immediately report signs\/symptoms of depression or suicidal ideation during treatment and up to 6 months after the last dose.<\/li><li>Instruct patient to report any visual disturbances, unusual bleeding or bruising, or signs\/symptoms of pulmonary disorders or infection.<\/li><li>Teach patient proper technique and placement of injections.<\/li><li>Advise patient to rotate injection sites.<\/li><li>Instruct patient to avoid drinking alcohol to reduce the chance of further liver injury.<\/li><li> If a dose is missed or up to 2 days late, patient should take dose as soon as possible. If the missed dose is more than 2 days late, patient should contact healthcare professional.<\/li><\/ul>"}]}